Leadership Team

Dinesh has built the clinical development group from the ground up, advancing three monoclonal antibodies (mAbs) into the clinic, including two in immunology and one in infectious disease.

Before joining Generate, Dinesh served as associate vice president in quantitative pharmacology within oncology early development at Merck. During his 10 years at Merck, Dinesh played a significant part in the early oncology dose finding and registration of KEYTRUDA™ for melanoma, non-small cell lung cancer (NSCLC) and multiple other cancer indications including the first tumor agnostic biomarker (e.g microsatellite instability-high or MSI-hi) approval for cancer using a basket trial design. Dinesh is considered a global expert in his field and has extensive drug development and regulatory experience with multiple modalities such as mAbs, antibody-drug conjugates, oncolytic viruses, bispecifics and cancer vaccines and has played a significant part in multiple oncology programs in early and late development. He has also been an opinion leader in the field of oncology dose finding and model informed drug development and presented at multiple FDA-AACR workshops and an invited speaker at the Oncology Center of Excellence at the FDA.

Earlier in his career, Dinesh held several leadership and scientific roles at Eli Lilly and Company for 15 years and led the pharmacokinetics/pharmacodynamics (PK/PD) Group in the United Kingdom from preclinical to late development across several therapeutic areas.

Dinesh has published more than 50 peer-reviewed papers and received his Ph.D. from the University of Manchester, United Kingdom, in the field of Population PK/PD in 1997.

Gevorg is a cross-disciplinary thinker whose scientific contributions span computer science, biophysics, and molecular biology. His research at Dartmouth College—where he held faculty appointments in computer science, biological sciences, and chemistry—focused on uncovering the principles that link protein sequence, structure, and function. This work led to foundational advances in data-driven protein modeling and design, ultimately laying the scientific groundwork for Generate.

Motivated by the belief that therapeutic discovery could be reimagined through machine learning and programmable biology, Gevorg co-founded Generate in partnership with Flagship Pioneering. The company embodies his conviction that the future of medicine lies in systematically generating, rather than searching for, new drugs.

He holds bachelor’s degrees in computer science and biochemistry, a PhD from the Massachusetts Institute of Technology, and completed postdoctoral training at the University of Pennsylvania. Gevorg received tenure at Dartmouth in 2017.

He has authored over 50 peer-reviewed publications in leading journals including Nature, Science, and PNAS, and has received recognition from the Alfred P. Sloan Foundation, NIH, NSF, and the American Cancer Society.

Before joining Generate, Beth served as the senior vice president and chief people officer at Tripadvisor for more than seven years. In this role, she was responsible for leading a global team of approximately 130 employees in more than 20 countries. Previously, Beth served as senior vice president of global human resources at Nuance Communications, as well as vice president and head of human resources at Sanofi’s Boston hub, where she provided HR support to 6,500 employees for Genzyme, Sanofi and Sanofi Pasteur, as well as remote field teams. She also served as vice president of human resources for Genzyme, where she worked for more than a decade before the company was acquired by Sanofi in 2011.

Beth is a part-time venture advisor at SemperVirens Venture Capital, and remains a board member of the Tripadvisor Foundation. In March 2023, she was named one of the Transform 10, recognizing the 10 most inspirational executive leaders leading transformation across their areas of influence and moving the world forward.

Beth graduated from Cornell University with a Bachelor of Arts degree in English.

Most recently, Daria was the vice president of infectious disease and vaccines and chief scientific officer of the Merck Cambridge Research site. Over her 30 year career at Merck, she held various positions of increasing responsibility within both the research and medical affairs organizations, managing cross-functional research teams covering antibiotic, antiviral and vaccine research, neuroscience discovery and innovative platform development teams. She led teams to discover and develop multiple drugs that have been approved, including antivirals for HIV, hepatitis C, and cytomegalovirus, as well as anti-bacterials. Notably, Daria led research efforts that identified the first-in-class HIV integrase inhibitor, which won the 2008 Prix Galien award.

Over the course of her esteemed career, Dr. Hazuda has received numerous awards and contributed to over 200 peer-reviewed publications.

Daria trained as a biochemist at the State University of New York at Stony Brook, and went on to complete a postdoctoral research fellowship in the department of immunology at Smith Kline, now known as GSK.

Most recently, Aarif served as chief scientific officer and head of research and development at Scribe Therapeutics, where he led platform development, biology discovery, and translational research for a CasX-based genome editing and epigenetic silencing platform, with an internal focus on cardiometabolic disease. Prior to his experience at Scribe, he was head of drug development and chief medical officer at Calico Life Sciences, where he helped transform the organization into a clinical-stage company, overseeing multiple investigational new drug and clinical trial application filings and advancing a pipeline of programs across immuno-oncology, neurodegeneration, and kidney disease. Earlier in his career, Aarif spent seven years at Amgen, where he founded and led the cardiometabolic disorders therapeutic area and contributed to the discovery and advancement of several novel clinical candidates, including programs now in late-stage development.

Aarif is a board‑certified physician with training in internal medicine and cardiology. He earned his BSE in chemical engineering from Princeton University and both his MD and MBA from Columbia University. He has held academic appointments at The University of Texas MD Anderson Cancer Center and Stanford University and has authored numerous peer‑reviewed publications.

Most recently, Laurie served as vice president of research and development, transplant and immunology at CSL Behring, where she led global clinical development programs and supported the office of the CMO, overseeing various drug candidate programs in the field of solid organ and hematopoietic stem cell transplantation, immunology and nephrology. Laurie also developed novel patient recruitment and regulatory strategies to support the advancement of late-stage clinical development programs.

Prior to her role at CSL Behring, she spent 12 years at GlaxoSmithKline (GSK). At GSK, Laurie guided respiratory and allergy candidates through late-stage development, including the TRELEGY ELLIPTA asthma program from Phase 2 through approval. She also played a key role in the design and execution of numerous Phase 2, 3 and 4 studies, including a large pediatric safety trial in asthma.

Laurie is a board-certified physician in pediatrics and allergy and immunology. She is a graduate of the University of Notre Dame and obtained her M.D. from the Ohio State University College of Medicine. Laurie completed a fellowship in allergy and immunology at Duke University Medical Center, where she subsequently joined the faculty in pediatrics and conducted research on primary immune deficiency syndromes and bone marrow transplantation in the neonatal period.

Before joining Generate, Sean was General Counsel and Senior Vice President at the leading healthcare company Baxter International Inc. Under his leadership, Sean successfully oversaw the legal, compliance, and government affairs for several key projects, including the largest acquisition in Baxter’s history, Hillrom, Inc.

Before that role, he was General Counsel, Senior Vice President and Secretary at Apollo Education Group. Previously, he was Vice President for Commercial Law and Corporate Law at Amgen and Vice President and Deputy General Counsel for Litigation at Fresenius Medical Care North America. Earlier in his career, Sean was a law firm partner at Foley & Lardner LLP and served as an Assistant U.S. Attorney in Chicago for eight years, prosecuting federal criminal cases.

Sean graduated summa cum laude from the University of Michigan with a bachelor’s degree in History and graduated magna cum laude from the Harvard Law School.

Since his appointment in 2021, Mike has helped lead Generate:Biomedicines’ growth as it pioneers Generative Biology®. During his tenure, the company completed its Series B and C financing rounds and raised more than $750 million prior to its initial public offering. In 2026, Generate completed its IPO, raising approximately $400 million to advance its platform and pipeline. These funding milestones have enabled continued investment in the company’s generative AI platform and a growing pipeline of protein therapeutics, including five clinical-stage molecules and multiple additional preclinical programs.

Mike has also been instrumental in forging significant partnerships with leading institutions, laying a strong foundation for future advancement. For example, in 2022, the company announced a collaboration with Amgen focused on developing protein therapies, which was later expanded in January 2024. Additionally, in 2023, Generate:Biomedicines announced strategic collaborations with the MD Anderson Cancer Center and Roswell Park Comprehensive Cancer Center, which aim to harness their respective strengths in specialized medical research and treatment modalities to deliver novel therapeutics in oncology and CAR-T cells respectively.

Before joining Generate:Biomedicines, Mike held several key leadership positions at Merck & Co., Inc. As Chief Marketing Officer, he was responsible for the Global Marketing and Brand Strategy of a diverse portfolio encompassing innovative medicines and vaccines, generating over $40 billion in revenue. His previous roles at Merck & Co. include serving as President of Global Vaccines and managing the company’s operations in Sweden and the UK.

In addition to his executive role at Generate:Biomedicines, Mike serves on the boards of Expedition Medicines, Harbinger Health, and PPG Industries. At PPG Industries, he is a member of the Audit Committee and the Sustainability and Innovation Committee.

Mike holds an MBA from Harvard Business School, a degree in Accounting and Finance from the London School of Economics, and a BA in Economics from Middlebury College.

Before joining Generate, Sahm spent several years in biotech leading Business Development and Strategy activities as a Chief Business Officer, particularly leading complex platform focused collaborations across multiple technologies and therapeutic areas. Prior to this, Sahm worked at Merck & Co. for seven years as a leader across business development, investor relations and strategy functions involving extensive commercial drug development experience. During this time, he established and led the global strategy and operations team for Merck’s growing oncology organization and served as interim Vice President and Global Product Leader for Merck’s portfolio of HPV Vaccines. Before Merck, Sahm was a strategy consultant with McKinsey & Company in Australia. Sahm holds a B.S. in chemical engineering from the University of New South Wales in Sydney and an MBA from Columbia Business School in New York City.

In 2024, Jason was named one of Boston Business Journal’s CFOs of the Year, recognizing his leadership in steering Generate:Biomedicines’ financial strategy through complex market conditions, securing one of the largest Series C raises of 2023 with $281 million, and fostering transformative collaborations with MD Anderson Cancer Center, Roswell Park Comprehensive Cancer Center, and an expanded agreement with Amgen.

Before joining Generate, Jason was at Goldman Sachs for 20 years, where he became a Managing Director and Partner. Most recently, he was based in London and co-managed healthcare investment banking for Europe, the Middle East and Africa. Previously, he served as the Global Head of Healthcare Mergers and Acquisitions. Over his career, he has completed more than 75 merger and acquisition and financing transactions valued at more than $400 billion.

Jason graduated magna cum laude from Brown University with a bachelor’s of science degree in chemistry. He attended the Johns Hopkins University School of Medicine. After medical school, he completed one year of a neurosurgical residency at Jackson Memorial Hospital and was awarded the Surgical Intern of the Year distinction. He continued his education at Yale Law School, where he earned his juris doctor degree and was editor-in-chief of the Yale Journal of Health Policy, Law, and Ethics.

Kym most recently spent three years in the Alphabet ecosystem as a senior advisor to Verily and Isomorphic Labs, two of Alphabet’s “bets” in healthcare. Previously, Kym was Chief Communications Officer (CCO) for several public companies including CVS Health, Vertex Pharmaceuticals and Baxter International Inc. An agency veteran, Kym was the Global Sector Chair for Health at Edelman, the world’s largest public relations firm, and held the same role at Ogilvy earlier in her career. She has been named a leading healthcare influencer by PR Week and Medical Marketing & Media many times over the years. Kym is a member of the board of directors of Public Policy Holding Co. (PPHC), a group of bipartisan government relations and public affairs firms, and the Multiple Myeloma Research Foundation (MMRF). She is a graduate of Northwestern University, with a B.S. in communications and political science.